- Home
- IFRX vs CATO Comparison
IFRX vs CATO Comparison
Compare IFRX & CATO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- CATO
- Stock Information
- Founded
- IFRX 2007
- CATO 1946
- Country
- IFRX Germany
- CATO United States
- Employees
- IFRX N/A
- CATO N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- CATO Clothing/Shoe/Accessory Stores
- Sector
- IFRX Health Care
- CATO Consumer Discretionary
- Exchange
- IFRX Nasdaq
- CATO Nasdaq
- Market Cap
- IFRX 53.5M
- CATO 57.6M
- IPO Year
- IFRX 2017
- CATO N/A
- Fundamental
- Price
- IFRX $1.14
- CATO $4.64
- Analyst Decision
- IFRX Strong Buy
- CATO
- Analyst Count
- IFRX 5
- CATO 0
- Target Price
- IFRX $7.40
- CATO N/A
- AVG Volume (30 Days)
- IFRX 1.0M
- CATO 205.0K
- Earning Date
- IFRX 11-07-2025
- CATO 08-21-2025
- Dividend Yield
- IFRX N/A
- CATO N/A
- EPS Growth
- IFRX N/A
- CATO N/A
- EPS
- IFRX N/A
- CATO N/A
- Revenue
- IFRX $191,224.00
- CATO $650,830,000.00
- Revenue This Year
- IFRX N/A
- CATO N/A
- Revenue Next Year
- IFRX $1,216.24
- CATO N/A
- P/E Ratio
- IFRX N/A
- CATO N/A
- Revenue Growth
- IFRX 54.36
- CATO N/A
- 52 Week Low
- IFRX $0.71
- CATO $2.19
- 52 Week High
- IFRX $2.82
- CATO $6.70
- Technical
- Relative Strength Index (RSI)
- IFRX 45.40
- CATO 68.77
- Support Level
- IFRX $1.45
- CATO $3.84
- Resistance Level
- IFRX $1.77
- CATO $4.73
- Average True Range (ATR)
- IFRX 0.21
- CATO 0.26
- MACD
- IFRX -0.04
- CATO 0.01
- Stochastic Oscillator
- IFRX 24.94
- CATO 74.07
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.